Proceeds from the financing will be used to develop clinical laboratory tests -- using next generation sequencing and other advanced technologies -- that will broadly analyze the relevant tumor genomic and other molecular information in individual patients' cancers and connect it with a knowledge base of clinical data to help oncologists personalize treatment.